35 Result(s)
within
Pierre Fenaux
Internal Medicine
-
Article
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro
Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controve...
-
Article
Open AccessHealth-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL in lo...
-
Article
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
There are few instances in oncology where reciprocal clinical and laboratory translation studies have accelerated the understanding of disease biology and treatment more so than the decade following the Food a...
-
Article
Molecular remission as a therapeutic objective in acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemog...
-
Article
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia
-
Article
Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia
-
Article
Open AccessA phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 ...
-
Article
Open AccessTP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a hig...
-
Article
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Islands of CD123high cells have been commonly described in the bone marrow of patients with chronic myelomonocytic leukemia (CMML). Using a multiparameter flow cytometry assay, we detected an excess of CD123+ mon...
-
Article
Open AccessSingle agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
-
Article
Open AccessOutcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (media...
-
Article
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?
Indications of allogeneic hematopoietic stem cell transplantation (HSCT) remain controversial in patients with lower risk myelodysplastic syndrome. We review prognostic factors in lower risk MDS, delineating p...
-
Article
Open AccessImpact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
-
Article
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study
-
Article
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy
Intra-tumor heterogeneity portends poor outcome in many cancers. In AML, a higher number of drivers worsens prognosis. The Shannon Index is a robust metric of clonal heterogeneity that accounts for the number ...
-
Article
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
-
Article
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease
-
Article
Open AccessPublisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
-
Article
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
The independent prognostic impact of specific dysplastic features in acute myeloid leukemia (AML) remains controversial and may vary between genomic subtypes. We apply a machine learning framework to dissect t...
-
Article
Open AccessLuspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
